0000790526false12/31Q12026xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesrdnt:centerrdnt:segmentrdnt:incentivePlanxbrli:purerdnt:productrdnt:customeriso4217:EURrdnt:securityrdnt:jointVenturerdnt:creditFacilityrdnt:tranche00007905262026-01-012026-03-3100007905262026-05-0800007905262026-03-3100007905262025-12-310000790526srt:AffiliatedEntityMember2026-03-310000790526srt:AffiliatedEntityMember2025-12-310000790526us-gaap:HealthCarePatientServiceMember2026-01-012026-03-310000790526us-gaap:HealthCarePatientServiceMember2025-01-012025-03-310000790526rdnt:CapitationArrangementsMember2026-01-012026-03-310000790526rdnt:CapitationArrangementsMember2025-01-012025-03-3100007905262025-01-012025-03-310000790526us-gaap:CommonStockMember2025-12-310000790526us-gaap:AdditionalPaidInCapitalMember2025-12-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310000790526us-gaap:RetainedEarningsMember2025-12-310000790526us-gaap:ParentMember2025-12-310000790526us-gaap:NoncontrollingInterestMember2025-12-310000790526us-gaap:CommonStockMember2026-01-012026-03-310000790526us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310000790526us-gaap:ParentMember2026-01-012026-03-310000790526rdnt:EquityIncentivePlanMemberus-gaap:CommonStockMember2026-01-012026-03-310000790526us-gaap:NoncontrollingInterestMember2026-01-012026-03-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310000790526us-gaap:RetainedEarningsMember2026-01-012026-03-310000790526us-gaap:CommonStockMember2026-03-310000790526us-gaap:AdditionalPaidInCapitalMember2026-03-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310000790526us-gaap:RetainedEarningsMember2026-03-310000790526us-gaap:ParentMember2026-03-310000790526us-gaap:NoncontrollingInterestMember2026-03-310000790526us-gaap:CommonStockMember2024-12-310000790526us-gaap:AdditionalPaidInCapitalMember2024-12-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000790526us-gaap:RetainedEarningsMember2024-12-310000790526us-gaap:ParentMember2024-12-310000790526us-gaap:NoncontrollingInterestMember2024-12-3100007905262024-12-310000790526us-gaap:CommonStockMember2025-01-012025-03-310000790526us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000790526us-gaap:ParentMember2025-01-012025-03-310000790526rdnt:EquityIncentivePlanMemberus-gaap:CommonStockMember2025-01-012025-03-310000790526rdnt:DeepHealthInc.Memberus-gaap:CommonStockMember2025-01-012025-03-310000790526us-gaap:NoncontrollingInterestMember2025-01-012025-03-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000790526us-gaap:RetainedEarningsMember2025-01-012025-03-310000790526us-gaap:CommonStockMember2025-03-310000790526us-gaap:AdditionalPaidInCapitalMember2025-03-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000790526us-gaap:RetainedEarningsMember2025-03-310000790526us-gaap:ParentMember2025-03-310000790526us-gaap:NoncontrollingInterestMember2025-03-3100007905262025-03-310000790526us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-03-310000790526us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-12-310000790526rdnt:CommercialInsurance1Member2026-01-012026-03-310000790526rdnt:CommercialInsurance1Member2025-01-012025-03-310000790526rdnt:Medicare1Member2026-01-012026-03-310000790526rdnt:Medicare1Member2025-01-012025-03-310000790526rdnt:Medicaid1Member2026-01-012026-03-310000790526rdnt:Medicaid1Member2025-01-012025-03-310000790526rdnt:WorkersCompensationPersonalInjury1Member2026-01-012026-03-310000790526rdnt:WorkersCompensationPersonalInjury1Member2025-01-012025-03-310000790526rdnt:OtherPayorsMember2026-01-012026-03-310000790526rdnt:OtherPayorsMember2025-01-012025-03-310000790526rdnt:HealthCareManagementServiceMember2026-01-012026-03-310000790526rdnt:HealthCareManagementServiceMember2025-01-012025-03-310000790526us-gaap:HealthCareOtherMember2026-01-012026-03-310000790526us-gaap:HealthCareOtherMember2025-01-012025-03-3100007905262023-06-070000790526srt:MinimumMemberrdnt:RestatedPlanMember2026-01-012026-03-310000790526srt:MaximumMemberrdnt:RestatedPlanMember2026-01-012026-03-310000790526srt:MinimumMemberrdnt:ProperyAndEquipmentNetMember2026-03-310000790526srt:MaximumMemberrdnt:ProperyAndEquipmentNetMember2026-03-310000790526srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2026-03-310000790526srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2026-03-3100007905262025-10-012025-10-310000790526rdnt:ImagingCentersMember2025-12-310000790526rdnt:ArtificialIntelligenceMember2025-12-310000790526rdnt:ImagingCentersMember2026-01-012026-03-310000790526rdnt:ArtificialIntelligenceMember2026-01-012026-03-310000790526rdnt:ImagingCentersMember2026-03-310000790526rdnt:ArtificialIntelligenceMember2026-03-310000790526rdnt:ManagementServiceContractsMember2026-03-310000790526rdnt:CovenantNotToCompeteMember2026-03-310000790526us-gaap:CustomerRelationshipsMember2026-03-310000790526rdnt:PatentAndTrademarksMember2026-03-310000790526rdnt:DevelopedTechnologySoftwareMember2026-03-310000790526us-gaap:TradeNamesMember2026-03-310000790526rdnt:CertificationsMember2026-03-310000790526rdnt:OtherFiniteLivedIntangibleAssetsMember2026-03-310000790526us-gaap:TradeNamesMember2026-03-310000790526us-gaap:SoftwareDevelopmentMember2026-03-310000790526rdnt:ManagementServiceContractsMember2025-12-310000790526rdnt:CovenantNotToCompeteMember2025-12-310000790526us-gaap:CustomerRelationshipsMember2025-12-310000790526rdnt:PatentAndTrademarksMember2025-12-310000790526rdnt:DevelopedTechnologySoftwareMember2025-12-310000790526us-gaap:TradeNamesMember2025-12-310000790526rdnt:CertificationsMember2025-12-310000790526rdnt:OtherFiniteLivedIntangibleAssetsMember2025-12-310000790526us-gaap:TradeNamesMember2025-12-310000790526us-gaap:SoftwareDevelopmentMember2025-12-310000790526us-gaap:LeaseholdImprovementsMember2025-01-012025-03-310000790526rdnt:SeeModeTechnologiesPteLtdMember2025-06-020000790526rdnt:FirstMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2025-06-020000790526rdnt:FirstMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMemberrdnt:NewCustomerContractsMember2025-06-020000790526rdnt:FirstMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2025-11-032025-11-030000790526rdnt:SecondMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2025-06-020000790526rdnt:ThirdMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2025-06-020000790526rdnt:ContingentMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2025-06-020000790526rdnt:SecondMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2026-03-310000790526rdnt:ThirdMilestoneConsiderationMemberrdnt:SeeModeTechnologiesPteLtdMember2026-03-310000790526rdnt:KolbRadiologyP.CMember2025-07-010000790526us-gaap:MonteCarloModelMemberrdnt:KolbRadiologyP.CMember2026-03-310000790526rdnt:KolbRadiologyP.CMemberrdnt:MeasurementInputRevenueRiskPremiumMember2025-07-010000790526rdnt:KolbRadiologyP.CMemberus-gaap:MeasurementInputPriceVolatilityMember2025-07-010000790526rdnt:KolbRadiologyP.CMemberrdnt:MeasurementInputOperationalLeverageRatioMember2025-07-010000790526rdnt:KolbRadiologyP.CMemberus-gaap:MeasurementInputCreditSpreadMember2025-07-010000790526rdnt:CIMARUKLimitedMember2025-11-102025-11-100000790526rdnt:FirstMilestoneConsiderationMemberrdnt:CIMARUKLimitedMember2025-11-100000790526rdnt:SecondMilestoneConsiderationMemberrdnt:CIMARUKLimitedMember2025-11-100000790526rdnt:FirstMilestoneConsiderationMemberrdnt:CIMARUKLimitedMembersrt:MinimumMember2025-11-100000790526rdnt:SecondMilestoneConsiderationMemberrdnt:CIMARUKLimitedMembersrt:MinimumMember2025-11-100000790526rdnt:FirstMilestoneConsiderationMemberrdnt:CIMARUKLimitedMembersrt:MaximumMember2025-11-100000790526rdnt:SecondMilestoneConsiderationMemberrdnt:CIMARUKLimitedMembersrt:MaximumMember2025-11-100000790526rdnt:CIMARUKLimitedMemberrdnt:MeasurementInputRevenueRiskPremiumMember2025-11-100000790526rdnt:CIMARUKLimitedMemberus-gaap:MeasurementInputPriceVolatilityMember2025-11-100000790526rdnt:CIMARUKLimitedMemberrdnt:MeasurementInputOperationalLeverageRatioMember2025-11-100000790526rdnt:CIMARUKLimitedMemberus-gaap:MeasurementInputCreditSpreadMember2025-11-100000790526rdnt:GleamerSASMember2026-03-020000790526rdnt:GleamerSASMemberrdnt:MeasurementInputRevenueRiskPremiumMember2026-03-310000790526rdnt:GleamerSASMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310000790526rdnt:GleamerSASMemberrdnt:MeasurementInputOperationalLeverageRatioMember2026-03-310000790526rdnt:GleamerSASMemberus-gaap:MeasurementInputCreditSpreadMember2026-03-310000790526rdnt:SeeModeTechnologiesPteLtdMember2025-12-310000790526rdnt:SeeModeTechnologiesPteLtdMember2026-01-012026-03-310000790526rdnt:SeeModeTechnologiesPteLtdMember2026-03-310000790526rdnt:KolbRadiologyP.CMember2025-12-310000790526rdnt:KolbRadiologyP.CMember2026-01-012026-03-310000790526rdnt:KolbRadiologyP.CMember2026-03-310000790526rdnt:CIMARUKLimitedMember2025-12-310000790526rdnt:CIMARUKLimitedMember2026-01-012026-03-310000790526rdnt:CIMARUKLimitedMember2026-03-310000790526rdnt:GleamerSASMember2025-12-310000790526rdnt:GleamerSASMember2026-01-012026-03-310000790526rdnt:GleamerSASMember2026-03-310000790526rdnt:SeeModeTechnologiesPteLtdMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2026-03-310000790526rdnt:SeeModeTechnologiesPteLtdMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2026-03-310000790526rdnt:SeeModeTechnologiesPteLtdMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2026-03-310000790526rdnt:SeeModeTechnologiesPteLtdMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310000790526rdnt:KolbRadiologyP.CMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2026-03-310000790526rdnt:KolbRadiologyP.CMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2026-03-310000790526rdnt:KolbRadiologyP.CMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2026-03-310000790526rdnt:KolbRadiologyP.CMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310000790526rdnt:CIMARUKLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2026-03-310000790526rdnt:CIMARUKLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2026-03-310000790526rdnt:CIMARUKLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2026-03-310000790526rdnt:CIMARUKLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310000790526rdnt:GleamerSASMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2026-03-310000790526rdnt:GleamerSASMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2026-03-310000790526rdnt:GleamerSASMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2026-03-310000790526rdnt:GleamerSASMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2026-03-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2026-03-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2026-03-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-12-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-12-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-12-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310000790526us-gaap:RestrictedStockMember2026-01-012026-03-310000790526us-gaap:RestrictedStockMember2025-01-012025-03-310000790526us-gaap:EmployeeStockOptionMember2026-01-012026-03-310000790526us-gaap:EmployeeStockOptionMember2025-01-012025-03-310000790526rdnt:JointVentureInterestMember2026-03-310000790526rdnt:FranklinImagingLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:GreaterBaltimoreDiagnosticImagingMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:AdvancedImagingAtSt.JosephMedicalCenterLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:CarrollCountyRadiologyLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:BaltimoreWashingtonImagingCenterLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:CalvertMedicalImagingCentersLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:MontgomeryCommunityMagneticImagingCtrLPMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:Mt.AiryImagingCenterLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:OrangeCountyRadiationOncologyLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:ArizonaDiagnosticRadiologyGroupLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:GlendaleAdvancedImagingCenterLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526rdnt:SantaMonicaImagingGroupLLCMemberrdnt:JointVentureInterestMember2026-03-310000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2026-03-310000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2025-12-310000790526rdnt:JointVentureInterestMember2025-12-310000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2026-01-012026-03-310000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2025-01-012025-03-310000790526us-gaap:CommercialPaperMember2025-06-120000790526us-gaap:CommercialPaperMember2025-07-012025-07-010000790526us-gaap:CommercialPaperMember2026-03-310000790526rdnt:RegionalRadiologyCenterMember2026-01-060000790526rdnt:NorthwestRadiologyNetworkPCMember2026-02-020000790526rdnt:BusinessAcquisitionsMember2026-03-310000790526rdnt:RegionalRadiologyCenterAndNorthwestRadiologyNetworkPCMember2026-01-062026-02-020000790526rdnt:RegionalRadiologyCenterAndNorthwestRadiologyNetworkPCMember2026-02-020000790526rdnt:GleamerSASMember2026-03-022026-03-020000790526rdnt:GleamerSASMemberus-gaap:DevelopedTechnologyRightsMember2026-03-020000790526rdnt:GleamerSASMemberus-gaap:CustomerRelationshipsMember2026-03-020000790526rdnt:GleamerSASMemberus-gaap:TradeNamesMember2026-03-020000790526rdnt:GleamerSASMemberus-gaap:OtherIntangibleAssetsMember2026-03-020000790526rdnt:GleamerSASMemberus-gaap:DevelopedTechnologyRightsMember2026-03-022026-03-020000790526rdnt:GleamerSASMemberus-gaap:CustomerRelationshipsMember2026-03-022026-03-020000790526rdnt:GleamerSASMemberus-gaap:TradeNamesMembersrt:MinimumMember2026-03-022026-03-020000790526rdnt:GleamerSASMemberus-gaap:TradeNamesMembersrt:MaximumMember2026-03-022026-03-020000790526rdnt:GleamerSASMemberus-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2026-03-022026-03-020000790526rdnt:GleamerSASMemberus-gaap:OtherIntangibleAssetsMembersrt:MaximumMember2026-03-022026-03-020000790526rdnt:DigitalHealthMember2026-01-012026-03-310000790526us-gaap:IntersegmentEliminationMemberrdnt:ImagingCentersMember2026-01-012026-03-310000790526us-gaap:IntersegmentEliminationMemberrdnt:DigitalHealthMember2026-01-012026-03-310000790526us-gaap:IntersegmentEliminationMember2026-01-012026-03-310000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember2026-01-012026-03-310000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember2026-01-012026-03-310000790526us-gaap:OperatingSegmentsMember2026-01-012026-03-310000790526rdnt:ImagingCentersMember2025-01-012025-03-310000790526rdnt:DigitalHealthMember2025-01-012025-03-310000790526us-gaap:IntersegmentEliminationMemberrdnt:ImagingCentersMember2025-01-012025-03-310000790526us-gaap:IntersegmentEliminationMemberrdnt:DigitalHealthMember2025-01-012025-03-310000790526us-gaap:IntersegmentEliminationMember2025-01-012025-03-310000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember2025-01-012025-03-310000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember2025-01-012025-03-310000790526us-gaap:OperatingSegmentsMember2025-01-012025-03-310000790526rdnt:BarclaysMember2026-03-310000790526rdnt:TermLoanMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:SecuredDebtMember2024-04-180000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2024-04-180000790526rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember2024-04-180000790526rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember2024-04-182024-04-180000790526rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember2024-11-260000790526rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember2024-11-262024-11-260000790526rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember2025-06-110000790526rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember2025-06-112025-06-110000790526rdnt:TermLoanMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:SecuredDebtMember2025-06-112025-06-300000790526rdnt:TermLoanMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:SecuredDebtMember2025-01-012025-06-100000790526us-gaap:SecuredOvernightFinancingRateSofrMemberrdnt:BarclaysCreditAgreementMemberus-gaap:SecuredDebtMember2025-01-012025-12-310000790526us-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMember2025-01-012025-12-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysTermLoanMember2025-12-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:OneMonthSecuredOvernightFinancingRateSOFRMemberrdnt:BarclaysTermLoanMember2025-12-310000790526us-gaap:SecuredOvernightFinancingRateSofrMemberrdnt:BarclaysCreditAgreementMemberus-gaap:SecuredDebtMember2026-01-012026-03-310000790526us-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMember2026-01-012026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysTermLoanMember2026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:OneMonthSecuredOvernightFinancingRateSOFRMemberrdnt:BarclaysTermLoanMember2026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMember2026-03-310000790526us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2024-11-262024-11-260000790526us-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2024-11-262024-11-260000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2026-01-012026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysMemberrdnt:FirstLienCreditAgreementMemberus-gaap:LineOfCreditMember2025-12-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysMemberrdnt:FirstLienCreditAgreementMemberus-gaap:LineOfCreditMember2026-03-310000790526rdnt:TermLoanMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2022-10-070000790526us-gaap:RevolvingCreditFacilityMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2022-10-070000790526rdnt:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2026-01-012026-03-310000790526rdnt:TermLoanMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2026-01-012026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2026-01-012026-03-310000790526us-gaap:RevolvingCreditFacilityMemberrdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMember2025-12-310000790526rdnt:FirstLienTermLoanMemberus-gaap:SecuredDebtMember2026-03-310000790526rdnt:FirstLienTermLoanMemberus-gaap:SecuredDebtMember2025-12-310000790526rdnt:RestatedAgreementMemberus-gaap:SecuredDebtMember2026-03-310000790526rdnt:RestatedAgreementMemberus-gaap:SecuredDebtMember2025-12-310000790526rdnt:EquipmentNotesPayableMembersrt:MinimumMember2026-03-310000790526rdnt:EquipmentNotesPayableMembersrt:MaximumMember2026-03-310000790526rdnt:EquipmentNotesPayableMember2026-03-310000790526rdnt:EquipmentNotesPayableMember2025-12-310000790526srt:MinimumMember2026-01-012026-03-310000790526srt:MaximumMember2026-01-012026-03-310000790526rdnt:A2006PlanMember2025-12-310000790526rdnt:A2006PlanMember2026-01-012026-03-310000790526rdnt:A2006PlanMember2026-03-310000790526us-gaap:EmployeeStockOptionMember2026-03-310000790526us-gaap:EmployeeStockOptionMember2026-01-012026-03-310000790526rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember2025-12-310000790526rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember2026-01-012026-03-310000790526rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember2026-03-310000790526rdnt:PerformanceBasedStockUnitsMember2024-10-012024-10-310000790526srt:MinimumMemberrdnt:PerformanceBasedStockUnitsMember2024-10-012024-10-310000790526srt:MaximumMemberrdnt:PerformanceBasedStockUnitsMember2024-10-012024-10-310000790526rdnt:PerformanceBasedStockUnitsMember2026-01-012026-03-310000790526rdnt:PerformanceBasedStockUnitsMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockUnitsMember2023-01-310000790526srt:MinimumMemberrdnt:PerformanceBasedStockUnitsMember2023-01-012023-01-310000790526srt:MaximumMemberrdnt:PerformanceBasedStockUnitsMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockUnitsMember2024-03-310000790526rdnt:RestatedPlanMember2026-03-310000790526rdnt:IntermountainMedicalImagingLLCMemberus-gaap:SubsequentEventMember2026-05-010000790526rdnt:IntermountainMedicalImagingLLCMemberus-gaap:SubsequentEventMember2026-05-012026-05-01

(Mark One)

☒     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

or

☐     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

(Exact name of registrant as specified in its charter)

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

The number of shares of the registrant’s common stock outstanding on May 8, 2026 was 78,634,236 shares.

The following table summarizes changes in the Company’s consolidated stockholders' equity, including noncontrolling interest, during the three months ended March 31, 2026 and March 31, 2025.

			Three Months Ended March 31,
			2026						2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss			$	(24,732)					$	(29,737)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization			44,967						35,483
Noncash operating lease expense			16,298						14,431
Equity in earnings of joint ventures, net of dividends			(1,069)						(2,599)
Amortization of deferred financing costs and loan discount			779						728
Loss on sale and disposal of equipment			2,591						402
Lease abandonment charges			—						5,388
Amortization of cash flow hedge			—						1,033
Non-cash change in fair value of interest rate swap			—						2,106
Stock-based compensation			31,375						28,494
Change in fair value of contingent consideration			(2,764)						—
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable			9,375						(14,306)
Other current assets			(6,172)						(7,206)
Other assets			(660)						(1,691)
Deferred taxes			(9,099)						5,137
Operating leases			(13,299)						(21,968)
Deferred revenue			234						128
Accounts payable, accrued expenses and other			31,148						25,658
Net cash provided by operating activities			78,972						41,481
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities and other acquisitions, net of cash acquired			(304,151)						(3,794)
Purchase of property and equipment and other			(69,932)						(48,833)
Proceeds from sale of equipment			277						23
Equity contributions in existing and purchase of interest in joint ventures			—						(4,147)
Collection of notes receivable			2,833						—
Net cash used in investing activities			(370,973)						(56,751)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable			(9,953)						(1,718)
Payments on term loan debt			(5,252)						(5,000)
Distributions paid to noncontrolling interests			(2,402)						(913)
Proceeds from issuance of common stock upon exercise of options			103						121
Net cash used in financing activities			(17,504)						(7,510)
EFFECT OF EXCHANGE RATE CHANGES ON CASH			(2,371)						83
NET DECREASE IN CASH AND CASH EQUIVALENTS			(311,876)						(22,697)
CASH AND CASH EQUIVALENTS, beginning of period			767,215						740,020
CASH AND CASH EQUIVALENTS, end of period			$	455,339					$	717,323
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest			$	17,073					$	18,010
Cash paid during the period for income taxes			$	519					$	272

We acquired equipment and certain leasehold improvements for approximately $68.9 million and $62.5 million during the three months ended March 31, 2026 and 2025, respectively, which were not paid for as of March 31, 2026 and 2025, respectively. The amounts due were recorded in our condensed consolidated balance sheet under accounts payable, accrued expenses and other.

During the three months ended March 31, 2026, we acquired certain assets from entities engaged in the practice of radiology or related businesses. These acquisitions included contingent consideration and holdbacks totaling $9.0 million that we had not paid for as of March 31, 2026. The accrued amounts are reflected in our condensed consolidated balance sheets under accrued expenses and other non-current liabilities.

We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At March 31, 2026, we operated directly or indirectly through joint ventures with hospitals, 435 centers located in Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging ("MRI"), computed tomography ("CT"), positron emission tomography ("PET"), nuclear medicine, mammography, ultrasound, diagnostic radiology ("X-ray"), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. In addition to our center operations, we have certain other subsidiaries that develop Artificial Intelligence ("AI") products and solutions that are designed to enhance interpretation of radiographic images. Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. For further financial information about these segments, see Note 5, Segment Reporting.

The consolidated financial statements include the accounts of RadNet, Inc. as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as “RadNet,” “we,” “us,” “our” or the “Company” in this report.

Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

VIEs that we consolidate as the primary beneficiary include professional corporations which are owned or controlled by individuals within our senior management and provide professional medical services for centers in Arizona, California, Delaware, Maryland, Florida and New York. These VIEs are collectively referred to as the “Consolidated Medical Group". RadNet provides non-medical, technical and administrative services to the Consolidated Medical Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Consolidated Medical Group has insignificant operating assets and liabilities, and de minimis equity. Substantially all cash flows of the Consolidated Medical Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Consolidated Medical Group. The creditors of the Consolidated Medical Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of the Consolidated Medical Group. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

The Consolidated Medical Group on a combined basis recognized $77.4 million and $58.2 million of revenue, net of management services fees to RadNet, for the three months ended March 31, 2026 and 2025, respectively. RadNet recognized $235.0 million and $238.6 million of total billed net service fee revenue for the three months ended March 31, 2026, and 2025, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.

In our condensed consolidated balance sheets at March 31, 2026 and December 31, 2025, we have included approximately $161.0 million and $137.5 million, respectively, of accounts receivable and approximately $41.4 million and $34.9 million of accounts payable and accrued liabilities related to the Consolidated Medical Group, respectively. The cash flows of the Consolidated Medical Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation.

At all of our centers not serviced by the Consolidated Medical Group, we have entered into long-term contracts with medical groups to provide professional services at those centers, including supervision and interpretation of diagnostic imaging procedures. The medical groups maintain full control over the physicians they employ. Through our management agreements, we make available to the medical groups the imaging centers, including all furniture, fixtures and medical equipment therein. The medical groups are compensated for their services from the professional component of the global net service fee revenue and after deducting management service fees paid to us, we have no economic controlling interest in these medical groups. As such, the financial results of these groups are not consolidated in our financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended March 31, 2026 and 2025 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2025.

There have been no material changes to the significant accounting policies we use and have explained in our annual report on Form 10-K for the fiscal year ended December 31, 2025. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2025.

REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to other centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Our service fee revenue is based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenue related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenue at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

Our total revenues for the three months ended March 31, 2026 and 2025 are presented in the table below. Our patient service revenue is displayed as the estimated service fee, broken down by classification of insurance coverage type, along with revenue generated from our management services and other sources such as software and AI.

EQUITY BASED COMPENSATION – We have one long-term incentive plan, which has been amended and restated on April 20, 2015, March 9, 2017, April 15, 2021, April 27, 2023, and most recently following approval by our stockholders at our annual stockholders meeting on June 7, 2023 (the “Restated Plan”). We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We evaluate performance-based awards to determine if it is probable that the vesting conditions will be met. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three years to five years and expire five years to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes, binomial lattice valuation or similar, valuation model. Those models require that our management make certain estimates concerning risk-free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees.

In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock (the "DeepHealth options"). No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan.

In connection with our acquisition of iCAD, Inc. on July 17, 2025, we assumed the iCAD, Inc. 2016 Stock Incentive Plan, as amended, and the iCAD, Inc. 2012 Stock Incentive Plan, as amended by Amendment No. 1 (collectively, the “iCAD Plans”), including outstanding option awards that became exercisable for shares of our common stock. No additional awards will be granted under the iCAD Plans.

See Note 7, Stock-Based Compensation, for more information.

ACCOUNTS RECEIVABLE - The vast majority of our accounts receivable are due under fee-for-service contracts from third-party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivable from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on factoring agreements are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long-term portion. Amounts remaining to be collected on these agreements were $2.6 million and $3.5 million at March 31, 2026 and December 31, 2025, respectively. We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis.

DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities. Deferred financing costs, net of accumulated amortization, were $1.5 million and $1.7 million as of March 31, 2026 and December 31, 2025, respectively.

See Note 6, Credit Facilities and Notes Payable for more information.

PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are provided using the straight-line method over their estimated useful lives, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.

BUSINESS COMBINATIONS - When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

Acquisition-related costs are expensed as incurred and are included in Cost of operations, excluding depreciation and amortization, in the condensed consolidated statements of operations. For the three months ended March 31, 2026 and March 31, 2025, such costs totaled approximately $3.5 million and $0.7 million, respectively.

GOODWILL - Goodwill at March 31, 2026 totaled $1,094.7 million. Goodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2025 noting no impairment, and we have not identified any indicators of impairment through March 31, 2026.

Activity in goodwill for the three months ended March 31, 2026 is provided below (in thousands):

The amount of goodwill that is expected to be deductible for tax purposes as of March 31, 2026 is $224.8 million.

INTANGIBLE ASSETS - Intangible assets are primarily related to our business combinations and software development. They include the estimated fair value of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names. The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at March 31, 2026 and December 31, 2025 are as follows (in thousands):

As of March 31, 2026:

*Excluding the three months ended March 31, 2026

As of December 31, 2025:

Total intangible asset amortization expense was $6.8 million and $3.1 million for the three months ended March 31, 2026 and March 31, 2025, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management services agreements are amortized over 25 years using the straight-line method. Developed technology is capitalized and amortized over the useful life of the software when placed into service. Trade names and IPR&D are reviewed annually for impairment, or when indicators of impairment are presented.

INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets, we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law, which enacts significant changes to the U.S. Tax and related laws. Some of the provisions of the new tax law that affect corporations include, but are not limited to, reinstatement of immediate expensing of domestic specified research or experimental expenditures, restoration of EBITDA as the base for calculating deductible business interest expense, modifications to international tax regimes, and reenactment of one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The impact of the tax law changes from OBBBA with respect to periods prior to enactment were recognized by the Company in the third quarter of 2025, and has been applied prospectively based on the effective dates of the tax law.

The enactment of the OBBBA did not have a material impact on the Company’s financial statements.

In 2021, the Organization for Economic Co-operation and Development ("OECD") announced an inclusive framework on base erosion and profit shifting including Pillar Two Model Rules defining the global minimum tax, which calls for taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-US tax jurisdictions have either recently enacted legislation to support certain components of Pillar Two Model Rules beginning 2024 (including the European Union Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. Though the model rules provide a framework for applying the minimum tax, countries may enact Pillar Two Model Rules slightly differently than the model rules and on different timelines and may adjust domestic tax incentives in response to Pillar Two Model Rules. On a long-term basis, we will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in all countries applicable to us. For 2026, we expect that we will meet one or more transactional safe harbor rules, and as such, we do not believe Pillar Two model will have an impact on our annual effective tax rate for the year ending December 31, 2026.

We recorded an income tax provision of $8.1 million, or an effective tax rate of 24.7%, for the three months ended March 31, 2026, compared to $3.4 million, or an effective tax rate of 10.3% for the three months ended March 31, 2025. The income tax rates for the three months ended March 31, 2026 diverge from the federal statutory rate due to (i) state taxes; (ii) foreign rate differentials; (iii) officer compensation limitation under IRC Section 162(m); (iv) nondeductible stock-based compensation expense; (v) transaction costs and other nondeductible expenses; partially offset by (vi) noncontrolling interests and windfall benefits on the exercise of stock-based compensation.

LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liability in our condensed consolidated balance sheets. Finance leases are included in property and equipment, accounts payable, accrued expenses and other, and long-term finance lease liability in our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component.

ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of March 31, 2026. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.

We closely monitor patient levels at our imaging centers and occasionally divest or shut down centers to maximize utilization rates. We may abandon low utilization leases and divert the patients to nearby centers. During the three months ended March 31, 2025, we closed several imaging centers with lower utilization and recognized lease abandonment charges of approximately $5.4 million in our Imaging Center segment. Of these amounts, $4.8 million were related to right-of-use assets impairment and $0.6 million were related to the write-off of leasehold improvements for the three months ended March 31, 2025.

COMPREHENSIVE LOSS - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) ("OCI") and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in OCI. The components of OCI for the three months ended March 31, 2026 and 2025 are included in the Condensed Consolidated Statements of Comprehensive Loss. The following is a reconciliation of Foreign Currency Translation amounts for the three months ended March 31, 2026 and 2025 is provided below (in thousands):

INTEREST ON SECURITIES - We recognized income from interest on securities of approximately $5.0 million and $7.7 million for the three months ended March 31, 2026 and 2025, respectively. This income is recorded within Other non-operating income in our Condensed Consolidated Statements of Operations.

COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.

On June 2, 2025, the Company, through its wholly owned subsidiary DH AI International Holdings, B.V., completed the acquisition of all the equity interests of See-Mode Technologies Pte. Ltd., a Singapore-based AI company specializing in medical imaging. As part of the purchase agreement, we agreed to pay up to $12.7 million in contingent consideration in RadNet common stock and cash, based on the achievement of three clinical and regulatory milestones:

First Milestone ($4.3 million): Payable upon successful implementation of the company’s thyroid ultrasound detection product at four RadNet imaging centers, and execution of at least two new customer contracts totaling $150,000 in aggregate annual contract value by March 31, 2026. On November 3, 2025, we settled the first milestone by issuing 27,673 shares of our common stock at an ascribed value of $2.1 million and $2.2 million in cash.

Second Milestone ($4.2 million): Payable upon FDA 510(k) clearance of the company’s breast ultrasound detection product, with submission required by March 31, 2026 and approval by December 31, 2026.

Third Milestone ($4.2 million): Payable upon FDA 510(k) clearance of a new ultrasound product, with submission required by June 30, 2027 and approval by March 31, 2028.

Each contingent amount is payable 50% in cash and 50% in RadNet common shares. As of March 31, 2026, the fair value of the contingent consideration was assessed based on the probability of milestone achievement and was determined by management to be 90% and 80% for the Second and Third Milestone, respectively.

On July 1, 2025, the Company completed the acquisition of substantially all the assets of Kolb Radiology P.C., a New York-based diagnostic imaging practice. As part of the purchase agreement, we agreed to pay up to $8.0 million in contingent consideration (“Earnout Consideration”) payable based on the financial performance of the acquired business over three consecutive twelve-month periods following the closing date.

As of March 31, 2026, the fair value of the contingent consideration was estimated to be $4.1 million using a Monte Carlo simulation under a risk-neutral framework that modeled projected MRI revenues and discounted expected payments at term-matched U.S. Treasury rates plus RadNet’s credit spread. Key assumptions included a 2.3% revenue risk premium, 15% revenue volatility, 50% operational leverage ratio, and 2.9% credit spread.

On November 10, 2025, the Company completed the acquisition of CIMAR (UK) Limited. The purchase agreement includes contingent consideration payable based on the achievement of specified recurring revenue targets.

The contingent consideration provides for aggregate payments of up to approximately $15.1 million and includes two performance-based milestones tied to recurring revenue generated during measurement periods between 2026 and 2028. Each milestone becomes payable only if at least 90% of the applicable revenue target is achieved, with payments proportionately reduced for achievement between 90% and 100% of the target.

Any contingent consideration earned is payable 50% in cash and 50% in RadNet common stock.

The fair value of the contingent consideration was estimated using a Monte Carlo simulation under a risk-neutral framework that projected revenue-based performance milestones, R&D Deferred Consideration, and discounted expected payments at term-matched U.S. Treasury rates plus RadNet's credit spread. Key assumptions as of March 31, 2026 included a 2.2% revenue risk premium, 25% revenue volatility, 60% operational leverage ratio, and 3% credit spread.

On March 2, 2026, the Company, through our wholly owned subsidiary DH AI International Holdings, B.V., completed the acquisition of all the equity interests of Gleamer SAS. As part of the purchase agreement, we agreed to pay up to €15.0 million in contingent consideration in cash, based upon the achievements of specified annual recurring revenue ("ARR") targets.

At the acquisition date, the Company recorded a contingent consideration liability of $8.6 million. The fair value of the contingent consideration was estimated using a Monte Carlo simulation model, which considered a range of potential ARR outcomes and calculated the present value of expected payments. Key assumptions as of March 31, 2026 included a 2% ARR risk premium, 18% ARR volatility, 75% operational leverage ratio, and a 2% credit spread.

The contingent consideration liability is remeasured at fair value each reporting period, with changes in fair value recognized in earnings. A tabular roll forward of contingent consideration is as follows (amounts in thousands):

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

Contingent Consideration:

The table below summarizes the estimated fair values of contingencies relating to our acquisitions that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands):

Long Term Debt:

The table below summarizes the estimated fair value and carrying amount of our Barclays Term Loans and Truist Term Loan long-term debt as follows (in thousands):